Holen Sie sich die Stockscreener-App
4.045
1.95%
-0.065
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$4.11
Offen:
$4.075
24-Stunden-Volumen:
11.00M
Relative Volume:
0.64
Marktkapitalisierung:
$1.81B
Einnahmen:
$263.44M
Nettoeinkommen (Verlust:
$-390.98M
KGV:
-3.6084
EPS:
-1.121
Netto-Cashflow:
$-336.24M
1W Leistung:
+16.47%
1M Leistung:
+17.15%
6M Leistung:
+65.16%
1J Leistung:
+126.40%
1-Tages-Spanne:
$3.95
$4.2502
1-Wochen-Bereich:
$3.465
$4.2502
52-Wochen-Spanne:
$1.66
$5.63
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Firmenname
Iovance Biotherapeutics Inc
Sektor
Branche
Telefon
(650) 260-7120
Adresse
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
4.045 | 1.84B | 263.44M | -390.98M | -336.24M | -1.121 |
VRTX
Vertex Pharmaceuticals Inc
|
436.90 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.46 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.98 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.32 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.94 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Hochstufung | Citizens | Mkt Perform → Mkt Outperform |
| 2025-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-16 | Herabstufung | UBS | Buy → Neutral |
| 2025-05-12 | Herabstufung | Truist | Buy → Hold |
| 2025-05-09 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-07-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-09-18 | Bestätigt | Barclays | Overweight |
| 2023-05-30 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-31 | Eingeleitet | Guggenheim | Neutral |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2021-06-10 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Herabstufung | Stifel | Buy → Hold |
| 2021-05-03 | Eingeleitet | Truist | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Eingeleitet | Mizuho | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-04-29 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-02-28 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-31 | Fortgesetzt | B. Riley FBR | Buy |
| 2018-07-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-04-10 | Hochstufung | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Bestätigt | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-01 | Bestätigt | B. Riley FBR, Inc. | Buy |
Alle ansehen
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
IOVA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Assessing Iovance Biotherapeutics (IOVA) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
IOVA Stock Slides As Guidance Tops Wall Street Expectations - StocksToTrade
IOVA Stock Slides After Q1 Miss As Amtagvi Growth Accelerates - timothysykes.com
IOVA News | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
Iovance Biotherapeutics to Present at Upcoming Conference - The Manila Times
IOVA Technical Analysis | Trend, Signals & Chart Patterns | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits
Iovance Biotherapeutics’ SWOT analysis: stock gains momentum on melanoma data - Investing.com
IOVA Stock Price, Quote & Chart | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
symbol__ Stock Quote Price and Forecast - CNN
Iovance Biotherapeutics, Inc.Common Stock (NQ: IOVA - The Chronicle-Journal
Iovance’s Terminated TIL Study Reshapes Expectations for Solid-Tumor Growth - TipRanks
What Iovance Biotherapeutics (IOVA)'s Amtagvi Momentum and Narrowing Losses Means For Shareholders - Sahm
Barclays Maintains Iovance Biotherapeutics (IOVA) Overweight Recommendation - MSN
Earnings call transcript: Iovance Biotherapeutics Q1 2026 misses EPS, revenue forecasts - Investing.com UK
IOVANCE (NASDAQ: IOVA) CCO reports RSU vesting and tax share withholding - Stock Titan
Iovance slips after Q1 miss amid in-line 2026 outlook - MSN
Iovance (IOVA): The Best Penny Stock to Buy Before It Explodes - Insider Monkey
Iovance Biotherapeutics | SCHEDULE 13G: Others - Moomoo
State Street (NASDAQ: IOVA) holds 17.45M shares, 4.2% stake - Stock Titan
Chardan Cuts Iovance (IOVA) Price Target, Keeps Buy Rating - Insider Monkey
FDA's Makary On Brink: Why Biotech And Pharma Investors Shouldn't Panic (Or Celebrate) - Seeking Alpha
10 Best US Stocks Under $5 to Buy - Insider Monkey
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - simplywall.st
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $11 - Moomoo
IOVA DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionIOVA - TMX Newsfile
Iovance Biotherapeutics (IOVA) Trailing Loss Improvement Tests Bearish Profitability Narratives - Sahm
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2026 Earnings Call Transcript - Insider Monkey
Why Iovance Biotherapeutics (IOVA) Is Up 5.7% After AMTAGVI-Driven Q1 Revenue Jump And Share Plan - Yahoo Finance
Is Iovance Biotherapeutics’ (IOVA) Stock Authorization Request Quietly Rewriting Its Financing Playbook? - Sahm
IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13% - TradingView
Iovance Therapeutics: Q1 Earnings Miss May Have Created A Buying Opportunity (NASDAQ:IOVA) - Seeking Alpha
A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $5 to $14 - Moomoo
Iovance Biotherapeutics Q1 Earnings Call Highlights - Barchart.com
Iovance Biotherapeutics Price Target Cut to $14.00/Share From $16.00 by Chardan Capital - Moomoo
TD Cowen Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Chardan Capital Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Cuts Target Price to $14 - Moomoo
H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Iovance Biotherapeutics Shares Drop After Q1 Results Miss - Moomoo
Earnings call transcript: Iovance Biotherapeutics Q1 2026 misses EPS forecast By Investing.com - Investing.com South Africa
IOVA Stock Holds Key Range As Biotech Traders Watch Support - StocksToTrade
Evaluating Iovance Biotherapeutics (IOVA) Valuation After A Sharp Short Term Share Price Rebound - Sahm
Iovance Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Earnings call transcript: Iovance Biotherapeutics Q1 2026 misses EPS forecast - Investing.com
IOVANCE BIOTHERAPEUTICS, INC. 1Q 2026: Revenue $71.43M, EPS $(0.19) — 10-Q Summary - TradingView
Strong Q1 growth at Iovance (NASDAQ: IOVA) with 2026 revenue guidance - Stock Titan
IOVA Stock Grinds Higher As Traders Track Biotech Turnaround - timothysykes.com
Iovance Biotherapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Finanzdaten der Iovance Biotherapeutics Inc-Aktie (IOVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Iovance Biotherapeutics Inc-Aktie (IOVA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Vogt Frederick G | Interim CEO & General Counsel |
Mar 05 '26 |
Option Exercise |
0.00 |
62,493 |
0 |
556,293 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Mar 05 '26 |
Option Exercise |
0.00 |
31,246 |
0 |
148,477 |
| Puri Raj K. | Chief Regulatory Officer |
Mar 05 '26 |
Option Exercise |
0.00 |
39,059 |
0 |
257,590 |
| BILINSKY IGOR | Chief Operating Officer |
Mar 05 '26 |
Option Exercise |
0.00 |
31,246 |
0 |
142,394 |
| Vogt Frederick G | Interim CEO & General Counsel |
Mar 02 '26 |
Option Exercise |
0.00 |
52,087 |
0 |
516,609 |
| BILINSKY IGOR | Chief Operating Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
12,307 |
0 |
118,051 |
| Puri Raj K. | Chief Regulatory Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
5,470 |
0 |
221,329 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
12,697 |
0 |
124,353 |
| Kirby Daniel Gordon | Chief Commercial Officer |
Feb 24 '26 |
Option Exercise |
0.00 |
120,000 |
0 |
173,546 |
| Kirby Daniel Gordon | Chief Commercial Officer |
Feb 10 '26 |
Option Exercise |
0.00 |
39,996 |
0 |
69,996 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):